Capsule
3 mg / 100 mg | 7 mg / 100 mg | 14 mg / 100 mg
Product Overview
Semaglutide Description1-6
Semaglutide is a synthetic glucagon-like peptide-1 receptor agonist (GLP-1 RA) that functions as an incretin mimetic. Incretins are hormones released from the gastrointestinal tract into the systemic circulation that support glycemic control and have been utilized in weight management. When administered orally, semaglutide is indicated for the following use:
Treatment of type 2 diabetes mellitus as an adjunct to diet and exercise
Data indicate that oral semaglutide may produce clinically meaningful outcomes for individuals seeking weight reduction. In a 68-week study, oral semaglutide was associated with an average weight decrease of approximately 15%.
Metformin Description7-9
Metformin is an oral biguanide used to improve glycemic control in adult and pediatric patients 10 years and older with type 2 diabetes mellitus (T2DM). The drug is often 1st line for patients with T2DM. The drug is indicated for
There is evidence that metformin facilitates weight loss and decreases the appetite of patients who are administered the drug.
Semaglutide1-6
Semaglutide is an incretin mimetic that works on the glucagon-like peptide-1 (GLP-1) receptor by binding and activating the GLP-1 receptor. It has 94% sequence homology to human GLP-1. GLP-1 medications regulate glucose metabolism after oral consumption of carbohydrates and fats. The drug increases insulin secretion by glucose-dependent insulin synthesis and in vivo secretion of insulin from pancreatic beta cells in the presence of elevated glucose levels. It also suppresses glucagon secretion, slows gastric emptying, reduces food intake, and promotes beta-cell proliferation.
Metformin7-9
As an antidiabetic medication, metformin reduces gluconeogenesis production in the liver, decreases absorption of glucose in the gastrointestinal tract, and increases insulin sensitivity and subsequently peripheral glucose uptake and utilization. The drug facilitates glucose utilization in skeletal and adipose tissue. Metformin is believed to facilitate weight loss by decreasing caloric intake by patients through gastrointestinal adverse effects and appetite is decreased by production of glucagon like peptide 1 production.
Common 3,4,7-9
Gastrointestinal: Nausea, vomiting, diarrhea, constipation, dyspepsia, headache, dizziness.
Contraindications & Precautions3,4,7-9
Contraindications:
Precautions:
WPPL operates as a 503A compounding pharmacy and prepares individualized prescription medications pursuant to provider direction. Compounded preparations are not reviewed, tested, or approved by the FDA.
This listing also includes commercially manufactured products for convenience; these items are not compounded by our pharmacy and are sold as provided by their manufacturers. Actual products in stock at time of dispensing may vary due to supply chain variability. Any statements regarding non-compounded products are manufacturer-supplied, have not been evaluated by the FDA, and are not intended to diagnose, treat, cure, or prevent any disease. WPPL does not verify or endorse any therapeutic claims made by manufacturers. Please refer to original labeling for complete product information.
EXPLORE MORE
Related Medications
Licensed to ship across the U.S.
Your orders arrive promptly and privately, delivered directly to your door.
Providers: Let’s Partner for Better Patient Care
If you are a physician, clinic, or practice seeking a dependable Compounding Pharmacy partner, WP Pharma Labs is here to help. With dedicated account setup, streamlined ordering and responsive service, we support your therapeutic goals with specialized compounds designed for your patients.
To check product availability, check on the status of an existing order, request refills:
orders@wppharmalabs.com
New providers setup / update an existing account:
newaccounts@wppharmalabs.com
